Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epix To Advance COPD, Alzheimer’s Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm moving ahead after failed depression trial.

You may also be interested in...

GSK/Epix Alzheimer’s Drug Starts Phase IIb

Firm tries again with PRX-03140/donepezil combo.

Epix Looks To Partner With Path Now Clear For Vasovist Approval

Epix will file an NDA in mid-2008 following positive results from reevaluation of the vascular imaging agent.

Epix Drops Depression Candidate After Second Study Failure

Alzheimer’s candidate in development with GlaxoSmithKline advances.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts